U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Development Tool (DDT) Qualification Programs
  5. Clinical Outcome Assessment (COA) Qualification Program
  6. DDT COA #000006: Asthma Daily Symptom Diary (ADSD)
  1. Clinical Outcome Assessment (COA) Qualification Program

DDT COA #000006: Asthma Daily Symptom Diary (ADSD)

Clinical Outcome Assessments (COA) Qualification Submissions
Office of Immunology and Inflammation (OII)
Division of Pulmonary, Allergy, and Critical Care (DPACC)

DDT COA Number
DDT COA #000006

Instrument Name
Asthma Daytime Symptom Diary (ADSD) and Asthma Nighttime Symptom Diary (ANSD)

Disease/Condition
Asthma

Concept of Interest
Severity of core defining asthma symptoms

Context of Use
Adolescent (12 -17 years) and adult patients

COA Type
PRO

Qualification Stage
In transition to 507 process 

Requestor(s)
Critical Path Institute: Patient-Reported Outcome (PRO) Consortium

Contact(s)
Sonya Eremenco

Date Accepted into CDER’s COA Qualification Program
November 17, 2010

Qualification Date
March 28, 2019
Qualification Statement

Submission and Regulatory Correspondence History

Qualification Submission Date FDA Submission Decision & Recommendations Date
Full Qualification Package 5/31/18 FDA Response (Accepted) 3/28/19
Back to Top